CAS: 502-42-1; Cycloheptanone

上下游产品

diazomethane methanol diethyl ether cyclohexanonecycloactanone α,α'-bis(furfurylidene)cycloheptanone Isonicotinoylhydrazono-cycloheptan 2,3-Pentamethylen-chinolin-4-carbonsaeure

Cycloheptanone Samp-Hydrazone置于selenium(Iv) Oxide,双氧水体系中,用 甲醇,水 作为反应溶剂,以93%的收率获得产物环庚酮
参考文献:An Efficient Protocol For The Oxidative Hydrolysis Of Ketone Samp Hydrazones Employing Seo2 And H2O2 Under Buffered (Ph 7) Conditions
标题:An Efficient Protocol For The Oxidative Hydrolysis Of Ketone Samp Hydrazones Employing Seo2 And H2O2 Under Buffered (Ph 7) Conditions
摘要:An Effective Oxidative Protocol For The Liberation Of Ketones From Samp Hydrazones Employing Peroxyselenous Acid Under Aqueous Buffered Conditions (Ph 7) Has Been Developed. The Procedure Proceeds Without Epimerization Of Adjacent Stereocenters Or Dehydration,In Representative Samp Alkylation And Aldol Reaction Adducts,Respectively.
DOI:10.1055/s-0029-1218352

专利信息

专利号:US-4910310-A
优先权日:1988-10-03
标 题:Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives
发明人：CAMPBELL ARTHUR L; BEHLING JAMES R; BABIAK KEVIN A; NG JOHN S; MUELLER RICHARD A; FLEET GEORGE W J
权利人:SEARLE & CO
摘要:Novel intermediates and method for the chemical synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives are provided. A preferred intermediate is 1,5-dideoxy-1,5-imino-3, 4-O-isopropylidene-L-fucitol which is used to prepare the HIV inhibitor 1,5-dideoxy-1,5-imino-[N-ω-methyl caproate]-L-fucitol. These compounds are prepared in a short synthesis from the known compound 2,3-O-isopropylidene-D-lyxono-1,4-lactone or in a multi-step synthesis from D-galactose.

专利号:US-7910623-B2
优先权日:2005-07-22
标 题 :Synthesis of scabronines and analogues thereof
发明人：DANISHEFSKY SAMUEL J; WATERS STEPHEN P
权利人:SLOAN KETTERING INST CANCER
摘要:A novel synthesis of scabronines, which are related to a broader class of angularly fused tricyclic diterpenoids known as cyathanes, is provided. Scabronine G, its methyl ester derivative, and other analogs have been shown to have neurotrophic activity. Therefore, these compounds are particularly useful in treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's diseases, etc. The invention provides for the synthesis of scabronines as well as analogs thereof. Pharmaceutical compositions and method of using the inventive compounds are also provided.

专利号:US-4870199-A
优先权日:1986-04-30
标题 :Processes for the synthesis of diprotected R[R*,S*]-3,5-dihydroxy-6-oxohexanoate esters
发明人：CHEN KAU-MING; HARDTMANN GOETZ E; KAPA PRASAD K; LEE GEORGE T; LINDER JEROME; WATTANASIN SOMPONG
权利人:SANDOZ PHARMACEUTICALS CORP
摘要:Process for the synthesis of compounds of the formula in R[R*,S*] enantiomeric form, wherein each P1 is independently an hydroxy group-protecting group, and R2z is C1-4alkyl, benzyl or allyl, comprising, as a key step when R2z is R2x, the reaction of the compound of the formula in (S) enantiomeric form with a compound of the formula Mg &cir& +2 ((-)OOC-CH2-COOR2x)2 to obtain a compound of the formula in (S) enantiomeric form, and, as a key step when R2z is R2y, the reaction of a compound of the formula in (S) enantioimeric form with a compound of the formula Li(+)(-)CH2-COOR2y to obtain a compound of the formula in (S) enantiomeric form, wherein R2x is primary or secondary C1-4alkyl, benzyl or allyl, R2y is C1-4alkyl not containing an asymmetric carbon atom, and R3' is methyl or ethyl, processes for the synthesis of compounds of the formula comprising reacting a compound of the formula with the reaction product of a strong base and a compound of the formula optionally followed by, when R2z is allyl, cleavage of the allyl and P1 groups to obtain the corresponding compound of the formula wherein each R7 is methyl or ethyl, R is as defined in the specification, and each P1 independently and R2z are as defined above, and the compounds of the formula wherein R and each R7 are as defined above.

专利号:US-7452994-B2
优先权日:2001-09-12
标 题 :Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
发明人：MCEACHERN ERNEST J; BRIDGER GARY J; SKUPINSKA KRYSTYNA A; SKERLJ RENATO T; YANG WEN
权利人:ANORMED INC
摘要:This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.

专利号:US-2006211858-A1
优先权日:2001-02-28
标 题 :Novel substituted calix (4) pyrroles and process for the synthesis of calix (4) pyrroles over molecular sieve catalysts
发明人：RAGHAVAN KONDAPURAM V; KULKARNI SHIVANAND J; KISHAN MOTKURI R; SRINIVAS NAGABANDI
权利人:RAGHAVAN KONDAPURAM V; KULKARNI SHIVANAND J; KISHAN MOTKURI R; SRINIVAS NAGABANDI
摘要:The present invention relates to novel calix pyrroles and a process for synthesis of calix (4) pyrroles by reacting pyrrole with cyclic or acyclic ketones in dichloro methane (DCM) solvent over molecular sieve catalysts which provides an eco-friendly, more economical and selective heterogeneous method.

专利号:US-10040752-B2
优先权日:2015-08-24
标 题 :Synthesis of levomethadone hydrochloride or dextromethadone hydrochloride and methods for use thereof
发明人：MKRTCHYAN GNEL; YAO QINGWEI
权利人:CODY LABORATORIES INC
摘要:Highly efficient methods for synthesis of levomethadone hydrochloride or dextromethadone hydrochloride are provided starting from D-alanine, or L-alanine, respectively, with retention of configuration. Methods for treating a subject are provided comprising administering a composition comprising an effective amount of levomethadone hydrochloride having not more than 10 ppm dextromethadone.